Company intelligence / Profile preview

Ventrix, Inc.

California, United Statesventrixbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Completed a Phase 1 study of VentriGel in patients who experienced a first, large ST elevation myocardial infarction (STEMI). Currently has a Phase 1 study for VentriGel in pediatric patients with Hypoplastic Left Heart Syndrome (HLHS) that is not yet recruiting (as of May 2025).

Therapeutic areas: Cardiovascular
Modalities: Biomaterial scaffoldExtracellular matrix hydrogel
Industry: Biotech

Drug pipeline

1 asset

VentriGel

Partnerships

Emory University

Beyond the preview

Go deeper on Ventrix, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ventrix, Inc..

Explore the full profile